Physician profile
Ching O Li
NPI 1437351558
$3,858.89
in general payments reported to CMS, 2019-2025
27 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $406 · 2021: $731 · 2022: $970 · 2023: $659 · 2024: $575 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $559.65 | 2020-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Abbvie INC. | $472.23 | 2022-2025 | |
| Allergan, INC. | $408.04 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $394.35 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $214.15 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $200.92 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| New World Medical,INC. | $190.79 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $174.10 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $147.99 | 2020-2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $146.84 | 2023-2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.99 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $116.64 | 2021-2022 | |
| Biotissue Holdings INC. | $111.02 | 2021-2025 | |
| Oyster Point Pharma, INC. | $91.93 | 2022-2024 | Tyrvaya |
| Amgen INC. | $82.85 | 2024 | Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $68.64 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $50.00 | 2023 | Tagrisso |
| Genentech USA, INC. | $40.27 | 2022-2023 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $38.55 | 2024-2025 | Baerveldt Glaucoma Implant (250), Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $38.35 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $35.85 | 2020-2021 | |
| Shire North American Group INC | $35.07 | 2019 | |
| Dompe US, INC. | $25.27 | 2024 | Oxervate |
| Merz North America, INC. | $22.99 | 2023 | Xeomin |
| Tearlab Corp | $22.36 | 2024 | Scoutpro Osmolarity System |
| Ivantis, INC | $14.50 | 2020 | |
| Horizon Therapeutics Plc | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.